# EIF4E

## Overview
The EIF4E gene encodes the eukaryotic translation initiation factor 4E (eIF4E), a critical protein involved in the initiation of mRNA translation in eukaryotic cells. As a member of the eukaryotic initiation factor family, eIF4E is primarily responsible for recognizing and binding the 7-methylguanylate cap structure at the 5' end of mRNA molecules, a key step in the recruitment of ribosomes to mRNA and the initiation of protein synthesis (Chen2023Biological). The protein's structure, characterized by a cap-binding pocket formed by conserved tryptophan residues, facilitates its interaction with other components of the translation initiation complex, such as eIF4G and eIF4E-binding proteins (4E-BPs) (Piserà2018Structure). EIF4E plays a pivotal role in regulating the translation of specific mRNAs that are crucial for cell growth, proliferation, and survival, thereby influencing various cellular processes and maintaining cellular homeostasis (Chen2023Biological). Its dysregulation is associated with several cancers, making it a target for therapeutic interventions (Graff2007Therapeutic).

## Structure
The eIF4E protein is a crucial component in the initiation of translation, binding to the m7G cap structure at the 5' end of most eukaryotic mRNAs. Its three-dimensional structure has been characterized in various organisms, including humans. The structure of eIF4E consists of eight antiparallel beta-strands and three alpha-helices on the dorsal surface (Piserà2018Structure). The cap-binding site is on the basal face of the pocket, and the cap structure is stacked between two highly conserved tryptophan residues (Chen2023Biological). The interaction between eIF4E and the cap is primarily determined by cation-pi bond stacking between the 7-methylguanine and two conserved tryptophan residues (Trp-56 and Trp-102 in human eIF4E-1) within the cap-binding pocket (Piserà2018Structure).

The dorsal surface of eIF4E, which is invariantly hydrophobic/acidic, is responsible for binding eIF4E partner proteins, including eIF4G and 4E-BPs. The consensus eIF4E-binding motif YXXXXLF allows for the binding of eIF4G and 4E-BPs with eIF4E (Piserà2018Structure). The eIF4E family includes multiple members, such as eIF4E-2 and eIF4E-3, which have different binding affinities and interactions (Piserà2018Structure). In humans, the EIF4E gene is located on chromosome 4 and encodes the eIF4E-1 factor, with alternative splicing resulting in multiple transcript variants (Piserà2018Structure).

## Function
EIF4E (eukaryotic translation initiation factor 4E) is a pivotal component of the eukaryotic translation initiation complex, primarily involved in the initiation phase of protein synthesis. It functions by binding to the 7-methylguanylate cap structure located at the 5' end of mRNA molecules. This binding is crucial as it facilitates the recruitment of ribosomes to the mRNA, thereby promoting the translation process. EIF4E's activity is predominantly observed in the cytoplasm, where it plays a significant role in regulating the translation of specific mRNAs that are essential for cell growth, proliferation, and survival.

The protein's ability to control the translation of particular mRNAs allows it to influence various cellular processes, including cell cycle progression and response to external growth signals. By modulating the synthesis of proteins involved in these pathways, EIF4E contributes to the maintenance of normal cellular functions and organismal homeostasis. Its regulatory role in translation initiation underscores its importance in ensuring that proteins are synthesized in response to the cell's needs, thereby supporting healthy cellular and organismal outcomes.

## Clinical Significance
The eIF4E gene is significantly implicated in various cancers due to its role in mRNA translation. Overexpression of eIF4E is linked to tumorigenesis and metastasis in cancers such as breast, lung, prostate, and head and neck cancers. This overexpression enhances the translation of growth-promoting proteins like VEGF and cyclin D1, contributing to cancer progression and poor prognosis (Chen2023Biological; Graff2007Therapeutic). In lung cancer, eIF4E acts as a key regulator of cell growth and survival, with its inhibition showing potential therapeutic effects (Chen2023Biological). 

In addition to solid tumors, eIF4E is associated with hematological malignancies, including leukemias and lymphomas, where its elevated levels promote angiogenesis and tumor growth (Graff2007Therapeutic). The phosphorylation of eIF4E is crucial for the translation of mRNAs involved in cancer progression, such as those encoding MMP3 and Snail, which are linked to epithelial-mesenchymal transition and metastasis (Siddiqui2015Signalling; Piserà2018Structure).

Therapeutic strategies targeting eIF4E, such as antisense oligonucleotides and small molecule inhibitors, have shown promise in reducing its expression and suppressing tumor growth without toxicity to normal tissues (Chen2023Biological; Graff2007Therapeutic).

## Interactions
EIF4E, a key component of the eukaryotic initiation factor 4F (eIF4F) complex, interacts with the 5' cap structure of mRNA, facilitating translation initiation. It binds to eIF4G, a scaffolding protein that enhances its cap-binding affinity and promotes the recruitment of the 40S ribosomal subunit to mRNA, crucial for cap-dependent translation (Gross2003Ribosome; Ptushkina1998Cooperative). The interaction between eIF4E and eIF4G is mediated by a conserved motif on eIF4G, which induces a conformational change in eIF4E, enhancing its cap-binding ability (Kamenska2014eIF4Ebinding).

EIF4E also interacts with eIF4E-binding proteins (4E-BPs), which compete with eIF4G for binding to eIF4E. 4E-BPs utilize a lateral surface on eIF4E distinct from the dorsal surface used by eIF4G, allowing them to displace eIF4G and inhibit translation initiation (Igreja20144EBPs). The phosphorylation state of 4E-BPs regulates their binding affinity to eIF4E, influencing translation initiation (Gross2003Ribosome).

In yeast, eIF4E also interacts with p20, which shares part of the eIF4G binding site on eIF4E but binds with lower affinity. This interaction can inhibit the formation of the eIF4E-eIF4G complex, acting as a fine regulator of translation (Ptushkina1998Cooperative).


## References


[1. (Graff2007Therapeutic) Jeremy R. Graff, Bruce W. Konicek, Thomas M. Vincent, Rebecca L. Lynch, David Monteith, Spring N. Weir, Phil Schwier, Andrew Capen, Robin L. Goode, Michele S. Dowless, Yuefeng Chen, Hong Zhang, Sean Sissons, Karen Cox, Ann M. McNulty, Stephen H. Parsons, Tao Wang, Lillian Sams, Sandaruwan Geeganage, Larry E. Douglass, Blake Lee Neubauer, Nicholas M. Dean, Kerry Blanchard, Jianyong Shou, Louis F. Stancato, Julia H. Carter, and Eric G. Marcusson. Therapeutic suppression of translation initiation factor eif4e expression reduces tumor growth without toxicity. Journal of Clinical Investigation, 117(9):2638–2648, September 2007. URL: http://dx.doi.org/10.1172/jci32044, doi:10.1172/jci32044. This article has 317 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci32044)

[2. (Igreja20144EBPs) Cátia Igreja, Daniel Peter, Catrin Weiler, and Elisa Izaurralde. 4e-bps require non-canonical 4e-binding motifs and a lateral surface of eif4e to repress translation. Nature Communications, September 2014. URL: http://dx.doi.org/10.1038/ncomms5790, doi:10.1038/ncomms5790. This article has 63 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/ncomms5790)

[3. (Ptushkina1998Cooperative) M. Ptushkina. Cooperative modulation by eif4g of eif4e-binding to the mrna 5’ cap in yeast involves a site partially shared by p20. The EMBO Journal, 17(16):4798–4808, August 1998. URL: http://dx.doi.org/10.1093/emboj/17.16.4798, doi:10.1093/emboj/17.16.4798. This article has 111 citations.](https://doi.org/10.1093/emboj/17.16.4798)

[4. (Kamenska2014eIF4Ebinding) Anastasiia Kamenska, Clare Simpson, and Nancy Standart. Eif4e-binding proteins: new factors, new locations, new roles. Biochemical Society Transactions, 42(4):1238–1245, August 2014. URL: http://dx.doi.org/10.1042/bst20140063, doi:10.1042/bst20140063. This article has 30 citations and is from a peer-reviewed journal.](https://doi.org/10.1042/bst20140063)

[5. (Chen2023Biological) Xiaocong Chen, Yang An, Mengsi Tan, Dongrui Xie, Ling Liu, and Benjin Xu. Biological functions and research progress of eif4e. Frontiers in Oncology, August 2023. URL: http://dx.doi.org/10.3389/fonc.2023.1076855, doi:10.3389/fonc.2023.1076855. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2023.1076855)

[6. (Piserà2018Structure) Arianna Piserà, Adele Campo, and Salvatore Campo. Structure and functions of the translation initiation factor eif4e and its role in cancer development and treatment. Journal of Genetics and Genomics, 45(1):13–24, January 2018. URL: http://dx.doi.org/10.1016/j.jgg.2018.01.003, doi:10.1016/j.jgg.2018.01.003. This article has 53 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.jgg.2018.01.003)

[7. (Gross2003Ribosome) John D. Gross, Nathan J. Moerke, Tobias von der Haar, Alexey A. Lugovskoy, Alan B. Sachs, John E.G. McCarthy, and Gerhard Wagner. Ribosome loading onto the mrna cap is driven by conformational coupling between eif4g and eif4e. Cell, 115(6):739–750, December 2003. URL: http://dx.doi.org/10.1016/s0092-8674(03)00975-9, doi:10.1016/s0092-8674(03)00975-9. This article has 283 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/s0092-8674(03)00975-9)

[8. (Siddiqui2015Signalling) Nadeem Siddiqui and Nahum Sonenberg. Signalling to eif4e in cancer. Biochemical Society Transactions, 43(5):763–772, October 2015. URL: http://dx.doi.org/10.1042/bst20150126, doi:10.1042/bst20150126. This article has 239 citations and is from a peer-reviewed journal.](https://doi.org/10.1042/bst20150126)